Previous Close | 1.6600 |
Open | 1.7400 |
Bid | 1.7300 x 4000 |
Ask | 1.7400 x 2900 |
Day's Range | 1.7000 - 1.7800 |
52 Week Range | 0.3700 - 2.2600 |
Volume | 2,278,441 |
Avg. Volume | 11,293,796 |
Market Cap | 346.8M |
Beta (5Y Monthly) | -0.10 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | Aug 12, 2020 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 4.25 |
RALEIGH, NC / ACCESSWIRE / March 1, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today the Company has appointed Michael Rice to its board of directors.
RALEIGH, NC / ACCESSWIRE / February 10, 2021 / 9 Meters Biopharma, Inc. (Nasdaq:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today announced that its Chief Executive Officer, John Temperato, will present a corporate overview and participate in one-on-one investor meetings at the BIO CEO & Investor Conference.
9 Meters Biopharma (NMTR) has moved higher as of late, but there could definitely be trouble on the horizon for this company.